Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Epilepsy, Brain Tumor Adult
Interventions: Focal cortical cooling; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland

Conditions: Fatigue Syndrome, Chronic
Interventions: Thermal Pain Stimulation, Physical Effort Stimulation; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more

Conditions: Diabetic Nephropathies
Interventions: Calcitriol, Losartan; Dietary Supplement · Drug
Lead sponsor: Weill Cornell Medical College in Qatar; Other
Eligibility: 21 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Suicide and Self-harm, Suicide, Suicide, Attempted, Suicidal Ideation
Interventions: Mobile Application to Prevent Suicide (MAPS), EMA Monitoring Only; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Recurrent Glioblastoma
Interventions: CART-EGFR-IL13Ra2 T cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2042
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mental and Behavioral Disorders, Mental Resilience, Emotional Awareness, Emotional Development
Interventions: ThinkHumanTV; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Sleep Architecture, Mild Traumatic Brain Injury, Sleep, Sleep and Circadian Problems
Interventions: Cognitive behavioral Therapy for insomnia (CBT-I); Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions: XL092, Atezolizumab, Avelumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 33 more

Conditions: Type 2 Diabetes Mellitus
Interventions: AR-C165395XX, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Atrial Fibrillation - Symptomatic
Interventions: Radiofrequency ablation; Procedure
Lead sponsor: Ohad Ziv; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreas Cancer, Cancer
Interventions: CivaSheet; Device
Lead sponsor: CivaTech Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Healthy
Interventions: Suction-assisted Lipoplasty, VASER-assisted lipoplasty; Device
Lead sponsor: Sound Surgical Technologies, LLC.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Miami, Florida • Toms River, New Jersey • Mentor, Ohio

Conditions: Suicide
Interventions: Safety Planning Intervention with Navigation Services; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 15 Years to 29 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Leukemia, Relapsed Adult Acute Lymphocytic Leukemia
Interventions: Lenalidomide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Male Factor Infertility
Interventions: PICSI dish; Device
Lead sponsor: Biocoat; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 801 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 9
States / cities: Laguna Hills, California • San Ramon, California • Atlanta, Georgia + 5 more

Conditions: Prostate Adenocarcinoma
Interventions: Fesoterodine, Placebo oral tablet; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pneumococcal Vaccines
Interventions: 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 835 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more

Conditions: Acute Lower Back Pain
Interventions: Chiropractic Care, Radial Extracorporeal Shockwave Therapy (ESWT) - Radial Pulse Therapy; Other
Lead sponsor: Northeast College of Health Sciences; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Seneca Falls, New York

Conditions: Diabetes Mellitus, Hypertension
Interventions: Web-based care management, Telephone and face-to-face care management, Internet access alone; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 25 Years to 79 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Brockton, Massachusetts

Conditions: Melanoma (Skin)
Interventions: CP-675,206; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Pre-exposure Prophylaxis, Substance Use Disorders
Interventions: Motivational Interviewing (MI), Contingency Management (CM); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Neuronal and Network Mechanisms of Electrocortical Stimulation

Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

Examining Feasibility, Acceptability, and Sustainability of a Novel Personalized Smartphone Intervention for Suicide - Randomized Trial

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Media and Mental Health

Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

VASER-Assisted Lipoplasty Compared With Suction-Assisted Lipoplasty

Suicide Prevention for Sexual and Gender Minority Youth (Open Trial)

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Comparative Clinical Trial: Manual Therapy With and Without Radial Extracorporeal Shockwave Therapy to Treat Acute Low Back Pain

Internet-based Diabetes Education and Case Management

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

PrEP Readiness Interventions for Supporting Motivation